UNASSIGNED: Relaxin is recognized as an ovarian polypeptide hormone. Abundant relaxin binding sites are observed in hypothalamic paraventricular nucleus (PVN). This study was conducted to determine the roles and underlying mechanisms of relaxin in the PVN in sympathetic activation and @entity101 in spontaneously @entity101 @entity35 (SHR). Experiments were performed in normotensive @entity35 -Kyoto @entity35 (WKY) and SHR. Relaxin and its @entity21414 receptors in PVN were up-regulated in SHR. Relaxin-positive neurons existed in both parvocellular and magnocellular parts of the PVN. Presympathetic neurons and @entity28207 neurons in the PVN expressed @entity21414 , but not relaxin. Bilateral PVN microinjection of @entity1 @entity7175 increased but anti-relaxin IgG reduced renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP), plasma @entity1063 (NE) and @entity5463 ( @entity28207 ) levels in SHR. The effects of @entity7175 on RSNA and MAP were abolished by intravenous infusion of ganglionic blocker @entity4033 , and attenuated by @entity28207 V1 receptor antagonist @entity6021 . @entity2308 phosphorylation was enhanced in SHR, and @entity7175 stimulated @entity2308 phosphorylation and p85a subunit of @entity21203 expression. @entity21203 inhibitor @entity2306 or @entity2308 inhibitor @entity17138 abolished the effects of @entity7175 on the RSNA, MAP and plasma NE, and attenuated the @entity7175 -induced @entity28207 secretion. @entity27576 and @entity27522 ( @entity27522 ) binding to relaxin-promoter were significantly increased in SHR. Chronic PVN infusion of @entity7175 with osmotic pumps in normal @entity35 induced sympathetic activation, @entity28207 secretion and @entity101 accompanied with @entity65 . Relaxin in the PVN contributes to sympathetic overdrive and @entity101 via @entity21203 - @entity2308 pathway.

Relaxin in paraventricular nucleus contributes to sympathetic overdrive and @entity101 via @entity21203 - XXXX pathway.

@entity1 :: ('9606', 'Species') :: ['human'] @entity4033 :: ('MESH:D018738', 'Chemical') :: ['hexamethonium'] @entity17138 :: ('MESH:C548887', 'Chemical') :: ['MK-2206'] @entity6021 :: ('MESH:C025043', 'Chemical') :: ['AAVP'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity7175 :: ('6019', 'Gene') :: ['relaxin-2'] @entity2308 :: ('24185(Tax:10116)', 'Gene') :: ['Akt'] @entity5463 :: ('MESH:D001127', 'Chemical') :: ['arginine vasopressin'] @entity21414 :: ('295144(Tax:10116)', 'Gene') :: ['RXFP1'] @entity2306 :: ('MESH:C085911', 'Chemical') :: ['LY294002'] @entity27522 :: ('83503(Tax:10116)', 'Gene') :: ['polymerase II', 'Pol II'] @entity28207 :: ('D001127', 'Chemical') :: ['AVP'] @entity27576 :: ('24918(Tax:10116)', 'Gene') :: ['STAT5a'] @entity35 :: ('10116', 'Species') :: ['Wistar', 'rats'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular remodeling'] @entity21203 :: ('298947(Tax:10116)', 'Gene') :: ['PI3K']
@entity2308 :: (24185(Tax:10116),Gene) :: ['Akt']
